賽升藥業(300485.SZ)擬斥不超1970萬元入股康樂衞士
格隆匯8月7日丨賽升藥業(300485.SZ)公佈,公司擬參與認購康樂衞士非公開發行股票。康樂衞士該次擬向賽升藥業以非公開形式總計發行100萬股的人民幣普通股,每股發行價格為人民幣19.70元,預計向賽升藥業募集資金總額不超過人民幣1970萬元。該次交易構成關聯交易。
康樂衞士成立於2008年0月14日,註冊資本7600萬元人民幣,法定代表人郝春利,其經營範圍包括生物技術開發、技術諮詢、技術轉讓、技術服務,貨物進出口、技術進出口、代理進出口;銷售醫療器械I類、II類、化學試劑,生產I類醫療器械,生產第II類醫療器械。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.